Grifols（1GRF）株式概要グリフォルスS.A.は、スペイン、米国、カナダ、および国際的に血漿治療会社として事業を展開している。 詳細1GRF ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長3/6過去の実績3/6財務の健全性1/6配当金3/6報酬当社が推定した公正価値より62.5%で取引されている 収益は年間20.39%増加すると予測されています 過去1年間で収益は112.6%増加しました 同業他社や業界と比較して、良好な取引価格 リスク分析利払いは収益で十分にカバーされない 財務結果に影響を与える大きな一時的項目 Italian市場と比較した過去 3 か月間の株価の変動不安定な配当実績 すべてのリスクチェックを見る1GRF Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€9.7832.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture010b2016201920222025202620282031Revenue €9.8bEarnings €545.8mAdvancedSet Fair ValueView all narrativesGrifols, S.A. 競合他社PhilogenSymbol: BIT:PHILMarket cap: €894.2mRecordati Industria Chimica e FarmaceuticaSymbol: BIT:RECMarket cap: €10.3bArterra BioscienceSymbol: BIT:ARBSMarket cap: €18.6mAlkermesSymbol: NasdaqGS:ALKSMarket cap: US$6.2b価格と性能株価の高値、安値、推移の概要Grifols過去の株価現在の株価€9.7852週高値€13.6052週安値€8.70ベータ1.171ヶ月の変化3.21%3ヶ月変化-18.31%1年変化5.84%3年間の変化-12.86%5年間の変化-58.09%IPOからの変化-67.80%最新ニュースお知らせ • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., SpainReported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.お知らせ • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.最新情報をもっと見るRecent updatesお知らせ • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., SpainReported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.お知らせ • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.お知らせ • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025お知らせ • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona SpainValuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.株主還元1GRFIT BiotechsIT 市場7D6.8%1.0%-0.3%1Y5.8%28.9%16.8%株主還元を見る業界別リターン: 1GRF過去 1 年間で28.9 % の収益を上げたItalian Biotechs業界を下回りました。リターン対市場: 1GRFは、過去 1 年間で16.8 % のリターンを上げたItalian市場を下回りました。価格変動Is 1GRF's price volatile compared to industry and market?1GRF volatility1GRF Average Weekly Movement6.9%Biotechs Industry Average Movement8.5%Market Average Movement5.2%10% most volatile stocks in IT Market8.4%10% least volatile stocks in IT Market3.1%安定した株価: 1GRFの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1GRFの weekly volatility ( 7% ) は過去 1 年間安定していますが、依然としてItalianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト190925,000Nacho Abia Buenachewww.grifols.comグリフォルス社は、スペイン、米国、カナダ、および国際的に血漿治療会社として事業を展開している。同社は、免疫不全症の治療に用いる免疫グロブリン、肝硬変、心循環不全、外傷、重度の熱傷などの病態生理学的状態における循環容積とタンパク質の損失を回復させるために用いるアルブミン、α-1として知られる遺伝性疾患の治療に用いる血漿タンパク質であるα-1プロテイナーゼ阻害剤を提供している；血友病Aやフォンウィルブランド病、血友病Bの治療に用いられる血液凝固因子である第VIII因子／フォンウィルブランド因子および第IX因子、遺伝性アンチトロンビン欠乏症の治療に用いられるアンチトロンビンIII、脾臓チロシンキナーゼ阻害剤であるフォスタマチニブ、外科的出血を抑制する生物学的封鎖剤として作用するフィブリノゲンと酵素トロンビンの組み合わせ、アルツハイマー病の治療に用いられるアルブミンとの血漿交換。また、診断検査機器、試薬、その他の機器の販売、生物学的製剤および製造サービスの提供、血漿の製造および第三者への販売も行っている。また、免疫薬「イムゴーIDP」、血液製剤「イムゴーPTI」、呼吸器製剤「プロラスチンバイアル」などを販売している。さらに、Xembify Pre-filled syringes、Gamunex Bags、FlexBag、Xembify Biweekly dosing、Fibrinogen、VISTASEAL、Prolastin-C AADT、Fostamatinib、Xembify - CLL、Albumina 20% and 5% 、Trimodulinを開発している；Alfa-1 AT 15%、GRF6019、GRF6021、Aßvac402、AKST4290、GIGA 2339、GIGA564、および前臨床段階にあるrecIG、Alfa-1 AT - 非嚢胞性線維症気管支拡張症、OSIG。カナダ血液サービス社とは、免疫グロブリン製剤の供給に関する提携契約を結んでいる。同社は1909年に設立され、スペインのバルセロナに本社を置いている。もっと見るGrifols, S.A. 基礎のまとめGrifols の収益と売上を時価総額と比較するとどうか。1GRF 基礎統計学時価総額€5.86b収益（TTM）€415.00m売上高(TTM)€7.44b15.7xPER（株価収益率0.9xP/Sレシオ1GRF は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1GRF 損益計算書（TTM）収益€7.44b売上原価€4.58b売上総利益€2.85bその他の費用€2.44b収益€415.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.61グロス・マージン38.36%純利益率5.58%有利子負債／自己資本比率109.9%1GRF の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.1%現在の配当利回り33%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 20:52終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Grifols, S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。32 アナリスト機関null nullBanco de Sabadell. S.A.Luis ArredondoBanco de Sabadell. S.A.Jaime EscribanoBanco Santander29 その他のアナリストを表示
お知らせ • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., Spain
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.
お知らせ • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.
お知らせ • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., Spain
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.
お知らせ • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.
New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.
Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.
New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.
Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.
お知らせ • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025
お知らせ • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona Spain
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.
